S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
With oil prices slumping, OPEC+ producers weigh more production cuts
Stop Trading Like A Turtle (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
With oil prices slumping, OPEC+ producers weigh more production cuts
Stop Trading Like A Turtle (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
With oil prices slumping, OPEC+ producers weigh more production cuts
Stop Trading Like A Turtle (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Laser breakthrough could send stock soaring 2,467% (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Laser breakthrough could send stock soaring 2,467% (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
With oil prices slumping, OPEC+ producers weigh more production cuts
Stop Trading Like A Turtle (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:BDTX

Black Diamond Therapeutics (BDTX) Stock Forecast, Price & News

$2.34
+0.19 (+8.84%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.10
▼
$2.38
50-Day Range
$1.43
▼
$2.34
52-Week Range
$1.18
▼
$4.08
Volume
131,379 shs
Average Volume
63,155 shs
Market Capitalization
$85.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

BDTX stock logo

About Black Diamond Therapeutics (NASDAQ:BDTX) Stock

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive BDTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Black Diamond Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BDTX Stock News Headlines

May 25, 2023 | finance.yahoo.com
Black Diamond Therapeutics Insider Ups Holding By 82% During Year
May 18, 2023 | finance.yahoo.com
Black Diamond Therapeutics Insider Ups Holding By 82% During Year \
June 4, 2023 | Behind the Markets (Ad)
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
May 14, 2023 | americanbankingnews.com
Wedbush Weighs in on Black Diamond Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:BDTX)
May 13, 2023 | americanbankingnews.com
FY2027 EPS Estimates for Black Diamond Therapeutics, Inc. Increased by Analyst (NASDAQ:BDTX)
May 11, 2023 | msn.com
Wedbush Reiterates Black Diamond Therapeutics (BDTX) Neutral Recommendation
May 9, 2023 | markets.businessinsider.com
Berenberg Bank Remains a Buy on Black Diamond Therapeutics (BDTX)
May 9, 2023 | finanznachrichten.de
Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
June 4, 2023 | Vantage Point (Ad)
We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
May 9, 2023 | finance.yahoo.com
Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
April 18, 2023 | finance.yahoo.com
Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
April 17, 2023 | tmcnet.com
Black Diamond Therapeutics Presents Trial in Progress Poster
April 17, 2023 | finance.yahoo.com
Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting
March 13, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: DarioHealth (DRIO), Fulcrum Therapeutics (FULC) and Black Diamond Therapeutics (BDTX)
March 9, 2023 | benzinga.com
Black Diamond Therapeutics shares are trading higher after the company reported better-than-expected Q4 EPS results.
March 9, 2023 | msn.com
Black Diamond Therapeutics GAAP EPS of -$0.59 beats by $0.04
March 9, 2023 | finance.yahoo.com
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 27, 2023 | finance.yahoo.com
Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
February 10, 2023 | morningstar.com
Black Diamond Therapeutics Inc Ordinary Shares
January 19, 2023 | finance.yahoo.com
private equity firms who own 40% along with institutions invested in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) saw increase in their holdings value last week
January 5, 2023 | finance.yahoo.com
Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 19, 2022 | finance.yahoo.com
Black Diamond Therapeutics Announces Changes to Board of Directors
December 12, 2022 | finance.yahoo.com
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
December 9, 2022 | finance.yahoo.com
Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)
December 9, 2022 | finance.yahoo.com
Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) recent US$17m market cap decline means a loss of US$21k for insiders who bought this year
December 6, 2022 | seekingalpha.com
Black Diamond Therapeutics: Selling For Large Discount To Cash
November 8, 2022 | finance.yahoo.com
Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
See More Headlines

BDTX Price History

BDTX Company Calendar

Last Earnings
3/09/2023
Today
6/04/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BDTX
CUSIP
N/A
CIK
1701541
Web
N/A
Phone
617-252-0848
Fax
N/A
Employees
86
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.39)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-91,170,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-69.30%
Return on Assets
-51.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.40
Quick Ratio
8.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.69 per share
Price / Book
0.87

Miscellaneous

Outstanding Shares
36,510,000
Free Float
33,201,000
Market Cap
$85.43 million
Optionable
Not Optionable
Beta
1.85

Key Executives

  • Dr. David M. Epstein Ph.D. (Age 63)
    Co-Founder, Pres, CEO & Director
    Comp: $854.73k
  • Dr. Fang Ni Pharm.D. (Age 35)
    CFO, Principal Financial Officer and Chief Bus. Officer
    Comp: $639.23k
  • Mr. Brent Hatzis-Schoch Esq.Mr. Brent Hatzis-Schoch Esq. (Age 57)
    J.D., COO & Gen. Counsel
    Comp: $610.48k
  • Dr. Elizabeth Buck Ph.D. (Age 47)
    Co-Founder & Chief Scientific Officer
  • Ms. Erika Jones (Age 37)
    VP of Fin., Corp. Controller & Principal Accounting Officer
  • Ms. Elizabeth L. Montgomery (Age 50)
    Chief People Officer
  • Dr. Christopher D. Roberts Ph.D.Dr. Christopher D. Roberts Ph.D. (Age 52)
    Advisor
  • Mr. Tai-An Lin Ph.D.
    Sr. VP of Translational Science & Discovery Biology
  • Dr. Sergey Yurasov M.D. (Age 53)
    Ph.D., Chief Medical Officer
  • Ms. Melanie Morrison
    Sr. VP of Devel. Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BDTX Stock - Frequently Asked Questions

How have BDTX shares performed in 2023?

Black Diamond Therapeutics' stock was trading at $1.80 on January 1st, 2023. Since then, BDTX stock has increased by 30.0% and is now trading at $2.34.
View the best growth stocks for 2023 here.

When is Black Diamond Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our BDTX earnings forecast.

How were Black Diamond Therapeutics' earnings last quarter?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) issued its quarterly earnings data on Thursday, March, 9th. The company reported ($0.59) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.04.

What other stocks do shareholders of Black Diamond Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Black Diamond Therapeutics investors own include Alector (ALEC), Alteryx (AYX), Editas Medicine (EDIT), Gossamer Bio (GOSS), Micron Technology (MU), NVIDIA (NVDA), Homology Medicines (FIXX), II-VI (IIVI), Intel (INTC) and Invitae (NVTA).

When did Black Diamond Therapeutics IPO?

(BDTX) raised $151 million in an IPO on Thursday, January 30th 2020. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Black Diamond Therapeutics' stock symbol?

Black Diamond Therapeutics trades on the NASDAQ under the ticker symbol "BDTX."

Who are Black Diamond Therapeutics' major shareholders?

Black Diamond Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include EcoR1 Capital LLC (3.26%), BlackRock Inc. (2.07%), Two Sigma Advisers LP (0.48%), Two Sigma Investments LP (0.30%), Dimensional Fund Advisors LP (0.07%) and Federated Hermes Inc. (0.04%). Insiders that own company stock include Bradley J Phd Bolzon, Brent Hatzis-Schoch, Christopher D Roberts, David M Epstein, Fang Ni, Growth N V Biotech, Robert Alexander Ingram, Thomas Leggett and Versant Venture Capital Vi, L.
View institutional ownership trends.

How do I buy shares of Black Diamond Therapeutics?

Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Black Diamond Therapeutics' stock price today?

One share of BDTX stock can currently be purchased for approximately $2.34.

How much money does Black Diamond Therapeutics make?

Black Diamond Therapeutics (NASDAQ:BDTX) has a market capitalization of $85.43 million. The company earns $-91,170,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis.

How can I contact Black Diamond Therapeutics?

Black Diamond Therapeutics' mailing address is 139 MAIN STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-252-0848 or via email at investors@bdtherapeutics.com.

This page (NASDAQ:BDTX) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -